Crispr Therapeutics AG (CRSP) stock has risen 53.09% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives CRSP stock a score of 64 out of a possible 100.
That rank is mainly influenced by a long-term technical score of 80. CRSP's rank also includes a short-term technical score of 69. The fundamental score for CRSP is 44. In addition to the average rating from Wall Street analysts, CRSP stock has a mean target price of 72. This means analysts expect the stock to add 24.59% over the next 12 months.
What's Happening with CRSP Stock Today
Crispr Therapeutics AG (CRSP) stock is up 7.34% while the S&P 500 is down -0.52% as of 9:57 AM on Monday, May 11. CRSP has risen $3.95 from the previous closing price of $53.84 on volume of 120,848 shares. Over the past year the S&P 500 has gained 3.66% while CRSP has risen 53.09%. CRSP earned $0.75 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 76.6.
Click Here to get the full Stock Score Report on Crispr Therapeutics AG (CRSP) Stock.
